Systematic Examination of Gene Expression and Proteomic Evidence Across Tissues Supports the Role of Mitochondrial Dysregulation in ME/CFS. — CFSMEATLAS
Systematic Examination of Gene Expression and Proteomic Evidence Across Tissues Supports the Role of Mitochondrial Dysregulation in ME/CFS.
Keele, Gregory R, Enger, Mike, Barnette, Quinn et al. · International journal of molecular sciences · 2026 · DOI
Quick Summary
Researchers analyzed genetic and protein data from multiple ME/CFS studies to look for common patterns. They found evidence that mitochondria—the energy-producing parts of our cells—may not be working properly in people with ME/CFS. The study identified specific genes and existing drugs that might help support mitochondrial function, though more research is needed to test whether these treatments actually work.
Why It Matters
This research provides molecular evidence that mitochondrial dysfunction is a real biological feature of ME/CFS rather than purely psychological, potentially validating patient experiences of energy deficits. Identifying existing approved drugs that may target mitochondrial dysfunction could accelerate repurposing efforts and clinical trials, offering hope for treatment options while waiting for novel therapeutics.
Observed Findings
MT-RNR1 and MT-RNR2 mitochondrial genes showed lower expression in ME/CFS cases across two independent studies.
Mitochondrial genes exhibited increased expression in platelet samples from ME/CFS patients in another dataset.
107 approved compounds were identified that target 26 genes relevant to mitochondrial support in muscle tissue.
83 approved compounds target 24 genes related to energy metabolism and mitochondrial function from GWAS data.
Limited consistency in specific gene signatures across different studies, highlighting phenotypic or methodological heterogeneity.
Inferred Conclusions
Mitochondrial dysregulation appears to be a consistent biological feature of ME/CFS across multiple independent datasets and tissues.
Existing approved pharmaceutical compounds may have potential to address mitochondrial dysfunction in ME/CFS and warrant further investigation.
The heterogeneity of ME/CFS may involve variable patterns of mitochondrial involvement, suggesting potential disease subtypes.
Remaining Questions
Why is there limited consistency in specific genes across studies—is this due to disease heterogeneity, tissue differences, or methodological variation?
Do any of the 107 and 83 identified compounds actually improve symptoms or mitochondrial function in ME/CFS patients when tested clinically?
What This Study Does Not Prove
This study does not prove that any of the identified drug compounds will actually be effective in treating ME/CFS patients—it only suggests they warrant investigation based on their molecular targets. The lack of consistency in specific genes across studies means these findings are preliminary, and larger, more rigorously controlled studies are needed to confirm which mitochondrial pathways are truly dysregulated. This work demonstrates association and mechanism in specific tissues but does not establish causation or explain the post-exertional malaise response.
Tags
Symptom:Post-Exertional MalaiseFatigue
Biomarker:Gene ExpressionBlood Biomarker
Method Flag:PEM Not DefinedExploratory OnlyMixed Cohort